Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

HIV Vaccine Research Team Loses $1.38M Grant

By Drug Discovery Trends Editor | July 9, 2014

In this July 1, 2014 file photo, former Iowa State University researcher Dong-Pyou Han leaves the federal courthouse in Des Moines, Iowa. An AIDS research team at Iowa State University will not get $1.4 million it had been awarded from the National Institutes of Health after Han, a team member, admitted to faking research results last year. Han has pleaded not guilty in federal court to four counts of making false statements in research reports. He is free on bond awaiting trial. (AP Photo/Charlie Neibergall, File)An AIDS research team at Iowa State University will not get the final $1.38 million payment of a National Institutes of Health five-year grant after a team member admitted last year to faking research results, the NIH said Tuesday.
 
One of the members of the research team, Dong-Pyou Han, has pleaded not guilty in federal court to four counts of making false statements in research reports. He is free on bond awaiting trial scheduled for Sept. 2.
 
The research team, led by biomedical sciences professor Michael Cho, was awarded $6.8 million to be paid over five years by the NIH, but it won’t see the last payment. The team previously received grants totaling $7.6 million.
 
The university has agreed to repay the government $496,000 for Han’s salary and other costs tied to his employment at ISU during the research. Han may not apply for or receive grants from the U.S. government for three years, the NIH said, but Cho’s team and other researchers at ISU can.
 
“NIH makes funding decisions based on scientific merit of the proposed research to eligible organizations/institutions. The researchers are eligible to apply for future NIH grant funding through their institutions just as other researchers may apply,” the agency said in an emailed statement.
 
University spokesman John McCarroll said the team, which consists of 10 researchers, has sufficient funding to continue its work. McCarroll said experts at federal agencies have told him it can take two to five years to recover from the negative perceptions created by a misconduct incident.
 
He said Cho continues to be a respected researcher and people seem to understand he was not aware of faked lab work.
 
“This has received national and international attention and I know he has been somewhat embarrassed by that and he doesn’t want to go through that again,” McCarroll said. Cho did not immediately respond to messages for comment.
 
According to the indictment filed last month in U.S. District Court in Des Moines, Han’s misconduct dates to when he worked at Case Western Reserve University in Cleveland under Cho, who was leading a team testing an experimental HIV vaccine on rabbits.
 
Starting in 2008, Cho’s team received initial NIH funding. Cho reported soon that his vaccine was causing rabbits to develop antibodies to HIV, which was considered a major breakthrough in HIV/AIDS vaccine research by NIH officials and the research community.
 
Iowa State recruited Cho in 2009, and his team – including Han – soon received a five-year grant to continue the research. The team reported progress until a group of researchers at Harvard University found in January 2013 the promising results had been achieved with rabbit blood spiked with human antibodies.
 
An ISU investigation pinpointed Han leading him to write in a Sept. 30, 2013, confession letter that he started the fraud in 2009 “because he wanted (results) to look better” and that he acted alone.
 
“I was foolish, coward, and not frank,” he wrote.
 
Han, 57, a native of South Korea, has been allowed by the court to live in Ohio near his family and travel to Iowa for court appearances.
 
Date: July 8, 2014
Source: Associated Press

Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE